Elicio therapeutics, inc. ELTX.US Overview
ELTX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
ELTX Current Performance
2.11%
Elicio therapeutics, inc.
-1.83%
Avg of Sector
-0.40%
S&P500
ELTX Key Information
ELTX Revenue by Segments
Browsing restrictions can be lifted for a fee.
ELTX Net Income
Browsing restrictions can be lifted for a fee.
ELTX Cash Flow
Browsing restrictions can be lifted for a fee.
ELTX Profit Margin
Browsing restrictions can be lifted for a fee.
ELTX PE Ratio River
Browsing restrictions can be lifted for a fee.
ELTX Financial Forecast
Browsing restrictions can be lifted for a fee.
ELTX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
ELTX Profile
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Price of ELTX
ELTX FAQ
When is ELTX's latest earnings report released?
The most recent financial report for Elicio therapeutics, inc. (ELTX) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ELTX's short-term business performance and financial health. For the latest updates on ELTX's earnings releases, visit this page regularly.
How much debt does ELTX have?
As of the end of the reporting period, Elicio therapeutics, inc. (ELTX) had total debt of 5.79M, with a debt ratio of 0.21. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ELTX have?
At the end of the period, Elicio therapeutics, inc. (ELTX) held Total Cash and Cash Equivalents of 19.03M, accounting for 0.68 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is ELTX's EPS continuing to grow?
According to the past four quarterly reports, Elicio therapeutics, inc. (ELTX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.87. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ELTX?
Elicio therapeutics, inc. (ELTX)'s Free Cash Flow (FCF) for the period is -10.12M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 16.5% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ELTX?
The latest valuation data shows Elicio therapeutics, inc. (ELTX) has a Price-To-Earnings (PE) ratio of -1.78 and a Price/Earnings-To-Growth (PEG) ratio of 0.07. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.